CTH-401 / Cartherics - LARVOL DELTA

Cartherics Raises Over $15 Million in Oversubscribed Private Financing Round to Advance Cell Therapy Programs (Businesswire) - "Cartherics Pty Ltd...is pleased to announce that it has successfully raised well over its target AU$15M in an oversubscribed financing round. This funding will support the clinical trial for CTH-401, the Company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases."

Financing • Ovarian Cancer

Cartherics to present and exhibit at Emergence 2024 (Cartherics Press Release) - "Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week...The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss: Cartherics’ breakthrough approach to treating solid tumours. How CTH-401, the company’s lead ‘off the shelf’ natural killer (NK) product, destroys ovarian cancer in mouse models and shows sustained efficacy; Clinical trials for CTH-401 in ovarian cancer planned for 2025; Cartherics’ proprietary scalable manufacturing process; The investment opportunity and avenues for shareholder liquidity....The company has...received clear advice on what is needed in the next 12 months to be ready to submit an IND for CTH-401. This will allow the company to begin clinical trials in Australia in 2025 and will represent a major value-creating milestone for the company."

Clinical • New trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

POSITIVE PRE-IND MEETING WITH US FDA FOR NEW OVARIAN CANCER CELL THERAPY (BioSpace) - "Cartherics Pty Ltd...is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its lead 'off-the-shelf' natural killer (NK) cell therapy product, CTH-401 for the treatment of ovarian cancer...'The pre-IND meeting for CTH-401 was a significant milestone for Cartherics and, based on the FDA’s guidance, we are confident that we’re on the path to a successful IND submission in early 2025'...initiation of the first clinical trial planned for early 2025."

FDA event • IND • New P1/2 trial • Ovarian Cancer